{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T20:39:13Z","timestamp":1786653553300,"version":"build-2736575974"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent in individuals with type 2 diabetes mellitus (T2DM). This study evaluated the effect of dapagliflozin on liver fat, liver stiffness, and visceral adiposity in patients with T2DM and MASLD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This was a single-arm, prospective, open-label interventional study with a paired design. Sixty-three patients with T2DM and moderate-to-severe hepatic steatosis on ultrasonography received dapagliflozin 10 mg daily for six months. Liver fat by dual-echo-magnetic resonance imaging (MRI), liver stiffness measurement (LSM) by fibroscan, and visceral adipose tissue (VAT) by dual X-ray absorptiometry were assessed at baseline and after six months. Response to therapy was defined as &gt;10% decrease in liver fat and &gt;15% decrease in LSM, respectively (Responders). Multivariable logistic regression analysis was performed to identify predictors of response with respect to change in liver fat and LSM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      After six months, mean weight decreased by 2.55 kg (3.23%) and HbA1c by 0.84%. MRI-liver fat percentage, LSM, and VAT volume declined by 2.7%, 0.85kPa, and 472 cm\n                      <jats:sup>3<\/jats:sup>\n                      , respectively (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001 for all). Change in VAT mass (\n                      <jats:italic toggle=\"yes\">r<\/jats:italic>\n                      = 0.546) and volume (\n                      <jats:italic toggle=\"yes\">r<\/jats:italic>\n                      = 0.437) correlated with change in liver fat, and change in aspartate aminotransferase (AST) correlated with change in LSM (\n                      <jats:italic toggle=\"yes\">r<\/jats:italic>\n                      = 0.351). Sixteen patients (25.4%) and 33 patients (52.4%) met the criteria for responders for liver fat and LSM, respectively. Baseline liver fat and LSM were independent predictors of decrease in liver fat and LSM, respectively in responders.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Dapagliflozin significantly reduced liver fat, liver stiffness, and visceral adiposity in patients with T2DM and MASLD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijem.ijem_1075_25","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T17:00:09Z","timestamp":1777568409000},"page":"157-163","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Effect of Dapagliflozin on Liver Fat, Liver Stiffness, and Visceral Adiposity in Patients with Type 2 Diabetes Mellitus and MASLD: An Open-Label Study from a Tertiary Care Centre"],"prefix":"10.4103","volume":"30","author":[{"given":"Bandana","family":"Dash","sequence":"first","affiliation":[{"name":"Department of Endocrinology, M.K.C.G Medical College, Berhampur, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padala","family":"Ravi Kumar","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, M.K.C.G Medical College, Berhampur, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak K.","family":"Dash","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, M.K.C.G Medical College, Berhampur, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debasish","family":"Patro","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, M.K.C.G Medical College, Berhampur, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradosh K.","family":"Sahu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, M.K.C.G Medical College, Berhampur, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandapaka V. K.","family":"Rao","sequence":"additional","affiliation":[{"name":"Department of Radiology, M.K.C.G Medical College, Berhampur, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"R1-20260430","doi-asserted-by":"crossref","first-page":"e0251","DOI":"10.1097\/HC9.0000000000000251","article-title":"The burden of nonalcoholic fatty liver disease is rapidly growing in every region of the world from 1990 to 2019","volume":"7","author":"Paik","year":"2023","journal-title":"Hepatol Commun"},{"key":"R2-20260430","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1016\/j.cgh.2023.04.015","article-title":"The global burden of liver disease","volume":"21","author":"Younossi","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R3-20260430","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.jceh.2021.11.010","article-title":"Prevalence of non-alcoholic fatty liver disease in India: A systematic review and meta-analysis","volume":"12","author":"Shalimar,","year":"2022","journal-title":"J Clin Exp Hepatol"},{"key":"R4-20260430","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes","year":"2018","journal-title":"Hepatology"},{"key":"R5-20260430","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1002\/oby.23263","article-title":"Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and non-alcoholic fatty liver disease","volume":"29","author":"Barb","year":"2021","journal-title":"Obesity (Silver Spring)"},{"key":"R6-20260430","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1080\/13696998.2024.2393952","article-title":"Budget impact of resmetirom for the treatment of adults with non-cirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis)","volume":"27","author":"Fishman","year":"2024","journal-title":"J Med Econ"},{"key":"R7-20260430","doi-asserted-by":"crossref","first-page":"e2267","DOI":"10.1210\/clinem\/dgac138","article-title":"Dapagliflozin improves body fat patterning, and hepatic and pancreatic fat in patients with type 2 diabetes in North India","volume":"107","author":"Ghosh","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"R8-20260430","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00125-018-4675-2","article-title":"Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: A double-blind randomised placebo-controlled study","volume":"61","author":"Eriksson","year":"2018","journal-title":"Diabetologia"},{"key":"R9-20260430","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2337\/dc18-1569","article-title":"The SGLT2 inhibitor dapagliflozin reduces liver fat but does not affect tissue insulin sensitivity","volume":"42","author":"Latva-Rasku","year":"2019","journal-title":"Diabetes Care"},{"key":"R10-20260430","doi-asserted-by":"crossref","first-page":"108610","DOI":"10.1016\/j.jdiacomp.2023.108610","article-title":"Effect of dapagliflozin on liver and pancreatic fat in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"37","author":"Shi","year":"2023","journal-title":"J Diabetes Complications"},{"key":"R11-20260430","article-title":"A meta-analysis of body composition changes associated with long-term use of sodium-glucose cotransporter-2 inhibitors","author":"Yamamoto","year":"2025","journal-title":"Endocr Pract"},{"key":"R12-20260430","doi-asserted-by":"crossref","first-page":"1203666","DOI":"10.3389\/fendo.2023.1203666","article-title":"Effect of sodium-glucose transporter 2 inhibitors on sarcopenia in patients with type 2 diabetes mellitus: A systematic review and meta-analysis","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R13-20260430","doi-asserted-by":"crossref","first-page":"110539","DOI":"10.1016\/j.mce.2019.110539","article-title":"Empagliflozin mitigates nonalcoholic fatty liver disease in high-fat-fed mice by alleviating insulin resistance, lipogenesis and endoplasmic reticulum stress","volume":"498","author":"Petito-da-Silva","year":"2019","journal-title":"Mol Cell Endocrinol"},{"key":"R14-20260430","doi-asserted-by":"crossref","first-page":"e123130","DOI":"10.1172\/jci.insight.123130","article-title":"SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms","volume":"4","author":"Osataphan","year":"2019","journal-title":"JCI Insight"},{"key":"R15-20260430","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J Clin Invest"},{"key":"R16-20260430","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s12072-024-10758-3","article-title":"Effects of dapagliflozin on liver steatosis in patients with non-alcoholic fatty liver disease","volume":"19","author":"Weng","year":"2025","journal-title":"Hepatol Int"},{"key":"R17-20260430","first-page":"e14974","article-title":"Effect of dapagliflozin on type 2 diabetes mellitus with non-alcoholic fatty liver disease","volume":"13","author":"Das","year":"2021","journal-title":"Cureus"},{"key":"R18-20260430","doi-asserted-by":"crossref","first-page":"e083735","DOI":"10.1136\/bmj-2024-083735","article-title":"Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis","volume":"389","author":"Lin","year":"2025","journal-title":"BMJ"},{"key":"R19-20260430","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3892\/br.2024.1904","article-title":"Dapagliflozin treatment alleviates fatty liver in patients with type 2 diabetes","volume":"22","author":"Gao","year":"2024","journal-title":"Biomed Rep"},{"key":"R20-20260430","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1111\/jgh.15580","article-title":"The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non-alcoholic fatty liver disease","volume":"36","author":"Phrueksotsai","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"key":"R21-20260430","doi-asserted-by":"crossref","first-page":"1024836","DOI":"10.3389\/fmed.2022.1024836","article-title":"Reappraisal of fibrosis-4 index and non-alcoholic fatty liver disease fibrosis score for advanced fibrosis in average-risk population","volume":"9","author":"Park","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"R22-20260430","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4103\/0971-3026.178281","article-title":"Comparative accuracy of CT, dual echo MRI and MR spectroscopy for preoperative liver fat quantification in living related liver donors","volume":"26","author":"Rastogi","year":"2016","journal-title":"Indian J Radiol Imaging"},{"key":"R23-20260430","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1016\/j.cgh.2023.03.041","article-title":"Clinical trial landscape in NASH","volume":"21","author":"Harrison","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R24-20260430","doi-asserted-by":"crossref","first-page":"650","DOI":"10.2337\/dc08-1863","article-title":"Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes","volume":"32","author":"List","year":"2009","journal-title":"Diabetes Care"},{"key":"R25-20260430","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.3390\/ijms23063107","article-title":"SGLT-2 inhibitors in NAFLD: Expanding their role beyond diabetes and cardioprotection","volume":"23","author":"Androutsakos","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R26-20260430","doi-asserted-by":"crossref","first-page":"116167","DOI":"10.1016\/j.bcp.2024.116167","article-title":"Dapagliflozin ameliorates hepatic steatosis via suppressing LXR\u03b1-mediated synthesis of lipids and bile acids","volume":"219","author":"Jin","year":"2024","journal-title":"Biochem Pharmacol"},{"key":"R27-20260430","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13098-020-00600-9","article-title":"Effects of dapagliflozin on serum and urinary uric acid levels in patients with type 2 diabetes","volume":"12","author":"Yuan","year":"2020","journal-title":"Diabetol Metab Syndr"},{"issue":"Suppl 1","key":"R28-20260430","first-page":"14","article-title":"Uric acid induces liver fibrosis through activation of inflammatory mediators and proliferating hepatic stellate cells in mice","volume":"75","author":"Sari","year":"2020","journal-title":"Med J Malaysia"},{"key":"R29-20260430","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1016\/j.cmet.2024.08.005","article-title":"SGLT2 inhibitor promotes ketogenesis to improve MASH by suppressing CD8\u207a T cell activation","volume":"36","author":"Liu","year":"2024","journal-title":"Cell Metab"},{"key":"R30-20260430","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2147\/DMSO.S233538","article-title":"Extraglycemic effects of SGLT2 inhibitors: A review of the evidence","volume":"13","author":"Bonora","year":"2020","journal-title":"Diabetes Metab Syndr Obes"},{"key":"R31-20260430","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.3390\/biomedicines13051098","article-title":"Adipokines and adipose tissue: The role and use of sodium-glucose co-transporter-2 inhibitors in patients with diabetes or heart failure","volume":"13","author":"Mazurkiewicz","year":"2025","journal-title":"Biomedicines"},{"key":"R32-20260430","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.curtheres.2017.07.002","article-title":"Effects of dapagliflozin on body composition and liver tests in patients with nonalcoholic steatohepatitis associated with type 2 diabetes mellitus","volume":"87","author":"Tobita","year":"2017","journal-title":"Curr Ther Res Clin Exp"}],"container-title":["Indian Journal of Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijem.ijem_1075_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:39:12Z","timestamp":1786649952000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijem.ijem_1075_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/ijem.ijem_1075_25","relation":{},"ISSN":["2230-8210","2230-9500"],"issn-type":[{"value":"2230-8210","type":"print"},{"value":"2230-9500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"2025-12-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-18","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}